Dr. John H. Krystal, USA
President, CINP

Prof. Barbara Sahakian, UKChair, CINP International
Scientific ProgrammeCommittee

Prof. Marina Picciotto, USA
Co-Chair, CINP International
Scientific ProgrammeCommittee

Prof. Siegfried Kasper, Austria
Chair, Local Organizing
Committee and CINP
President-ElectDates for yourDiary
July 2017

Launch of conference programme/ Call for poster abstracts
and award applications

July 2017

Registration Open

12th Jan 2018

First deadline for early registration fee

12th Jan 2018

Deadline for poster abstract submission

12th Jan 2018

Deadline for Award applications

12th Jan 2018

Deadline for speaker abstracts for accepted symposia

12th May 2018

Second deadline for registration fee

16th June 2018

Opening Ceremony of CINP 2018

Preliminary Programme
Key
Saturday 16th June 201809.00-10.30

11.00-12.30

SAT1

14.30-16.00

SAT2

16.45-18.00

Welcome andAwards Ceremony

PCW1
Holly Lisanby
TMS
PCW1
Eduard Vieta
Bipolar
PCW3
Joseph Zohar
PTSD

PL - Plenary
S - Symposia
CP – Clinical Perspectives
PCW/ WS – Pre-Conference
Workshop/ Education Workshop
CO – Corresponding Organisations

Sunday 17th June 201808.3008.45

Opening Address

08.4509.30

PL01: The environmentand resilience againstmental illness
Andreas Meyer
Lindenberg, Germany

09.4511.30

Others
S1: GABA regulation:from mechanisms tonovel therapeutictargets

11.3013.00
13.0014.30

14.4516.30

Schizophrenia
PTSD
ADD
Others
S2 : The use of
S3: PTSD Genetics in S4: ADHD across the S5: CINP initiative fortechnology in mental a military context
lifespan - biologicalpublic private
illness and mental
mechanisms underlying partnerships (PPPs)
wellbeing
disease onset andfor innovative CNS
persistence,drug development
implications fortreatment

Poster Session and Lunch
SAT3SAT4

Depression
OthersS6: New approaches in S7: New insights intotranscranial magnetic
the role ofstimulation fororbitofrontal cortex indepression
compulsive behavior
psychopathology andits treatment

16.4517.30

PL02: Suicidal subtypes:
improving phenotypes
to uncover underlying
biosignatures
Maria A Oqendo, USA

18.0019.30

SAT6

SAT7

SAT5

Women's Symposium

CO1

Details to follow

Details to follow

Bipolar Disorders
Addictive Disorders
Depression
S8: Strategies to
S9: Cannabis shapes
S10: Glutamate andpreventthe morophologfical mood disorders: All isneurobehavioraland epigenetic
not explained byprogression andtrajectory ofNMDA
suicide in bipolar mesocorticolimbic brain
disorderdevelopment relevant
to psychiatricvulnerability

SAT8

CP01
Addiction

WS01
Bipolar Disorders
The place of CINP
treatment guidelines forbipolar disorder inclinical practice:controversies andconsensus

CP02
Schizophrenia

WS02
Childhood andAdolescent Disorders
Advances in thediagnosis of paediatricmood disorders

Monday 18th June 201808.4509.30

09.4511.30

11.3013.00
13.0014.30

PL03: Molecularmechanisms of gene x
environment interactions- implications fordiagnosis and treatmentof psychiatric disorders
Elisabeth Binder,
Germany
Depression

Depression

S11 : Prediction of
disease vulnerability andtreatment response inmood and anxiety
disorders

S12: Translational
research on
etiopathogenesis oflate-life cognitive
impairment anddepression: four
different approaches
toward the common
goal

Presidential
symposium
Details to follow

SAT10

OCD

S13: A translational
approach to reducing
drug-related
memories andenhancing selfcontrol in drug
addiction

S14: Translational
neuroscience ofobsessivecompulsive
disorders

Young Scientist
Committee Meeting

Poster Session and Lunch
SAT9

Addictive Disorders

PL04: Modeling andpredicting developmental
trajectories of
16.45neuropsychiatric17.30
dimensions
Noboru Hiroi, USASAT12

SAT13

WS03

S15: Schizophrenia:
Progress of the
From genes toneuroscience-basedchanged brain
nomenclaturefunction(NbN) for
Psychotropic drugs

CO2

SAT11

Depression
Depression
Addictive Disorders
Schizophrenia
S16: The antidepressant S17: It's all in the wiring:
S18: Behavioural S19: Dopamine signal
controversy: what do
Brain circuits involved in addiction: a researchintensity in
14.45- reanalyses of controlled
depression andand clinical update
neuropsychiatric16.30 trials reveal regarding the antidepressant actions
disorders: etiology
true efficacy ofand therapy
antidepressants?

18.0019.30

Schizophrenia

SAT14

LATE BREAKING
S20

CP03
Rapid acting
antidepressants

WS04

Tuesday 19th June 201808.4509.30

09.4511.30

PL05: A circuits-first
approach to mental illness
Amit Etkin, USADepression

OCD

S21: Understanding themechanism of action of
ketamine-like drugs inmood disorders and theirimplementation in theclinic

S22: Deep brain
stimulation for severe
OCD: effect andmechanisms of STNand nucleus
accumbens targets

11.3013.00

13.0013.45

Depression

Schizophrenia

S23: Recent updates S24 : Neuroimaging
S25: NMDAR
on controversialin the treatment ofdysfunction,issues in the
depression - acuteneuromodulatory
management ofneuronal response,
dysfunction andschizophrenia
treatment effects
glutathione deficit inand recurrence
schizophrenia
prediction
pathogenesis

Poster Session and Lunch

CP04

WS05

Treatment
Resistant
Depression

Neuropsychopharmacology of theendocannabinoidome

General Assembly

CO3

Depression

LATE BREAKING

CP05

S30

Anxiety Disorders
and OCD

PL06: Glutamatergic
GABAergic anddopaminergic
abnormalities inantipsychotic-naive firstepisode schizophrenia
patients: connecteddisturbances orindependent biomarkers
for outcome?
Birte Glenthoej, Denmark
Others

13.4515.30

Schizophrenia

OthersSchizophrenia

S26: Microbiome andS27: Psychedelic
S28: Developing new
S29: Genes
neuropsychiatry - moving
medicine: themedications for theepigenome andtowards mechanisms
therapeutic potential oftreatment ofenvironment inmind-alteringschizophrenia:
pathophysiology ofsubstances
failures and hopes
brain illness

15.3016.15

PL07: Differentialinfluence of pre- and early
postnatal cannabis
exposure on thedeveloping brain
Tibor Harkany, Austria

16.1516.30

Closing ceremony

Early Bird Registration

Now Open!
Deadline 12th January 2018www.cinp.org/vienna